title: Seroprevalence of HIV-1, HIV-2, and HIV-1 group O in Nigeria: evidence for a growing increase of HIV infection.
abstract: To determine current data on HIV infection and to further confirm the presence of HIV-1 group O infection in Nigeria, 2300 samples from five states were tested for the presence of HIV antibody. A convenience sampling was obtained from pregnant women, tuberculosis (TB) patients, commercial sex workers (CSWs), blood donors, patients with sexually transmitted diseases (STDs), patients with skin diseases, male clients of CSWs, outpatients suspected to have AIDS, truck drivers, and community dwellers. With the exception of pregnant women, the HIV prevalences in all these groups were high: 60.6% in CSWs, 16.2% in TB patients, 7.7% in blood donors in some states, and 16% in the rural area of Kano State. Male clients of CSWs, truck drivers, and STD patients had prevalences of 7.8%, 8.6%, and 21.2%, respectively. Regional differences in relation to HIV prevalences were observed; HIV-2 and most of the HIV-1/2 infections were found in the southern states of Nigeria. Higher HIV prevalences were observed in the north-northeast in pregnant women, TB patients, and CSWs, but for blood donors, higher rates were seen in the southeast-southwest. One asymptomatic 50-year-old woman, a community dweller in Kano, was identified to be HIV-1 group O-positive. Compared with data from national surveillance studies in 1991/1992 and 1993/1994, a substantial increase in HIV infection was observed. Our results show a growing incidence of HIV infection in Nigeria and suggest the presence of a rural HIV epidemic. The identification of HIV-1 group O in Kano shows that this virus strain is geographically widespread in Nigeria.
authors.affiliation: HIV Screening Centre, University of Calabar, Nigeria.
authors.forename: E
authors.initials: E
authors.lastname: Esu-Williams
authors.forename: C
authors.initials: C
authors.lastname: Mulanga-Kabeya
authors.forename: H
authors.initials: H
authors.lastname: Takena
authors.forename: A
authors.initials: A
authors.lastname: Zwandor
authors.forename: K
authors.initials: K
authors.lastname: Aminu
authors.forename: I
authors.initials: I
authors.lastname: Adamu
authors.forename: O
authors.initials: O
authors.lastname: Yetunde
authors.forename: I
authors.initials: I
authors.lastname: Akinsete
authors.forename: D
authors.initials: D
authors.lastname: Patrel
authors.forename: M
authors.initials: M
authors.lastname: Peeters
authors.forename: E
authors.initials: E
authors.lastname: Delaporte
mesh_terms: D000328:Adult; D005260:Female; D015483:HIV Antibodies / Q000032:analysis; D015658:HIV Infections / Q000453:epidemiology* / Q000276:immunology; D015528:HIV Seroprevalence / Q000639:trends*; D015497:HIV-1 / Q000276:immunology; D015498:HIV-2 / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009549:Nigeria / Q000453:epidemiology; D011247:Pregnancy
chemical_list: D015483:HIV Antibodies